Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Disulfiram-associated hypercholesterolemia

E L Rogers, S M Naseem

    Alcoholism, Clinical and Experimental Research
    |January 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Disulfiram causes hypercholesterolemia in rats by increasing hepatic HMG-CoA reductase activity. This effect on cholesterol levels is reversible upon drug discontinuation.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The role of inflammation-related genes in osteoarthritis.

    Osteoarthritis and cartilage·2015
    Same author

    Microcystin-induced activation of prostaglandin synthesis and phospholipid metabolism in rat hepatocytes.

    Toxicology in vitro : an international journal published in association with BIBRA·2010
    Same author

    Community partnering and coalition development: finding solutions to oral health care problems together.

    Journal of dental education·2001
    Same author

    Stereotactic breast biopsy: a six-year surgical experience.

    The Journal of the Kentucky Medical Association·2001
    Same author

    Comparative binding and toxicity of saxitoxin and saxitoxinol in mice and in cultured cells.

    Biochemistry and molecular biology international·1997
    Same author

    Time for medical education reform.

    Academic medicine : journal of the Association of American Medical Colleges·1996
    Same journal

    COVID-19 pandemic-related changes in utilization of telehealth and treatment overall for alcohol use problems.

    Alcoholism, clinical and experimental research·2022
    Same journal

    The relationship between fathers' heavy episodic drinking and fathering involvement in five Asia-Pacific countries: An individual participant data meta-analysis.

    Alcoholism, clinical and experimental research·2022
    Same journal

    Screening for hazardous alcohol use in the Emergency Department: Comparison of phosphatidylethanol with the Alcohol Use Disorders Identification Test and the Timeline Follow-back.

    Alcoholism, clinical and experimental research·2022
    Same journal

    Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels.

    Alcoholism, clinical and experimental research·2022
    Same journal

    College students' virtual and in-person drinking contexts during the COVID-19 pandemic.

    Alcoholism, clinical and experimental research·2022
    Same journal

    Does state repeal of alcohol exclusion laws increase problem drinking?

    Alcoholism, clinical and experimental research·2022
    See all related articles

    Area of Science:

    • Biochemistry
    • Pharmacology
    • Toxicology

    Background:

    • Disulfiram is a medication used to treat alcohol dependence.
    • Hypercholesterolemia is a condition characterized by high cholesterol levels.
    • The potential effects of disulfiram on cholesterol metabolism are not fully understood.

    Purpose of the Study:

    • To investigate the association between disulfiram administration and hypercholesterolemia in a rat model.
    • To elucidate the underlying mechanism of disulfiram-induced hypercholesterolemia.

    Main Methods:

    • Rats were administered disulfiram at a dose of 15 mg/kg/day for 3 weeks.
    • Serum cholesterol levels were measured.
    • Hepatic HMG-CoA reductase activity was assessed.

    Related Experiment Videos

    Main Results:

    • Disulfiram administration led to a significant increase (25%) in serum cholesterol levels.
    • The observed hypercholesterolemia was reversible after discontinuing disulfiram.
    • A fourfold increase in hepatic HMG-CoA reductase activity was observed, indicating a key role in cholesterol biosynthesis.

    Conclusions:

    • Disulfiram is associated with reversible hypercholesterolemia in rats.
    • The mechanism involves the upregulation of hepatic HMG-CoA reductase, a critical enzyme in cholesterol synthesis.
    • These findings highlight a potential adverse effect of disulfiram that warrants clinical consideration.